Advertisement

Migräne pp 85-102 | Cite as

Prophylaxe

  • Hans-Christoph Diener
Chapter
Part of the Optimierte Arzneimitteltherapie book series (ARZNEIMITTELTH.)

Zusammenfassung

Patienten mit sehr häufigen und schweren Migräneattacken sollten eine Prophylaxe erhalten. Dies dient nicht nur der Reduktion der Schwere und Häufigkeit der Attacken, sondern hilft auch, einen medikamenteninduzierten Dauerkopfschmerz zu vermeiden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneiverordnungsreport (1996). Schwabe/Pfaffrath (Hrsg.), Georg Fischer VerlagGoogle Scholar
  2. Buring JE, Peto R, Hennekens CH (1990) Low-dose aspirin for migraine prophylaxis. JAMA 264:1711–1713PubMedCrossRefGoogle Scholar
  3. Diener HC, Brune K, Gerber W-D, Göbel H, Pfaffenrath V (1997) Behandlung der Migräneattacke und Migräneprophylaxe. Dtsch Ärztebl 94:A3092–A3102Google Scholar
  4. Diener HC, Föh M, Iaccarino C, Wessely P, Isler HR, Strenge H, Fischer M, Wedekind W, Taneri Z (1996) Cyclandelate in the prophylaxis of migraine: A randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 16:441–447PubMedCrossRefGoogle Scholar
  5. Diener HC, Limmroth V (1994) The treatment of migraine. Rev Contemp Pharmacother 5:271–284Google Scholar
  6. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS (1992) Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 19:340–345PubMedGoogle Scholar
  7. Havanka-Kanniainen H, Hokkanen E, Myllylä VV (1988) Long acting propranolol in the prophylaxis of migraine. Comparison of the daily doses of 80 mg and 160 mg. Headache 28:607–611PubMedCrossRefGoogle Scholar
  8. Holroyd KA, Penzien DB, Cordingley GE (1991) Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31:333–340PubMedCrossRefGoogle Scholar
  9. Horowski R (1983) Pharmacological effects of lisuride and their potential role in further research. In: Calne DB, Horowski R, McDonald RJWW (Hrsg.) Lisuride and Other Dopamine Agonists. Raven Press, New York, 127–139Google Scholar
  10. Klapper J, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group (1997) Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17:103–108PubMedCrossRefGoogle Scholar
  11. Mastrosimone F, Iaccarino C, de Caterina G (1992) Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine. J Med 23:1–11PubMedGoogle Scholar
  12. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL (1995) Migraine prophylaxis with divalproex. Arch Neurol 52:281–286PubMedGoogle Scholar
  13. Migraine-Nimodipine European Study Group M (1989) European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 29:633–638CrossRefGoogle Scholar
  14. Peatfield RC, Fozard JR, Rose CF (1986) Drug treatment of migraine. In: Clifford Rose F (Hrsg.) Handbook of Clinical Neurology, Vol. 4 (48): Headache. Elsevier Science Publishers B.V., Amsterdam, 173–217Google Scholar
  15. Peikert A, Wilimzig C, Köhne-Volland R (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16:257–263PubMedCrossRefGoogle Scholar
  16. Pfaffenrath V, Scherzer S (1995) Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia S15:14–20Google Scholar
  17. Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Göbel H, Fischer M (1996) Magnesium in the prophylaxis of migraine — a double-blind, placebo-controlled study. Cephalalgia 16:436–440PubMedCrossRefGoogle Scholar
  18. Sargent J, Solbach P, Damasio H, Baumel B, Corbett J, Eisner L, Jessen B, Kudrow L, Mathew N, Medina J, Saper J, Vijayan N, Watson C, Alger J (1985) A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 25:320–324PubMedCrossRefGoogle Scholar
  19. Schellenberg R, Bölsche F, Schwarz A, Thorn M, Gerber WD, Niederberger U, Soyka D, Wedekind W (1994) Cyclandelate versus propranolol. Clinical and neurophysiological control of therapeutic efficacy in prophylaxis of migraine. Results of a double blind study. In: Clifford Rose F (Hrsg.) New Advances in Headache Research Vol 4. Smith-Gordon, London, 141–148Google Scholar
  20. Scholz E, Gerber WD, Diener HC, Langohr HD, Reinecke M (1987) Dihydroer-gotamine versus flunarizine versus nifedipine versus metoprolol versus propranolol in migraine prophylaxis. A comparative study based on time series analysis. In: Clifford Rose F (Hrsg.) Advances in Headache Research. John Libey & Co, London, 135–145Google Scholar
  21. Silberstein SD (1996) Divalproex sodium in headache: Literature review and clinical guidelines. Headache 36:547–555PubMedCrossRefGoogle Scholar
  22. Verspeelt J, De Locht P, Amery WK (1996) Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia 16: 328–336PubMedCrossRefGoogle Scholar
  23. Welch KMA (1993) Drug therapy of migraine. New Engl J Med 329:14761482PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Hans-Christoph Diener
    • 1
  1. 1.Klinik und Poliklinik für NeurologieUniversität EssenEssenDeutschland

Personalised recommendations